Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma

@inproceedings{Li2017SynergisticEO,
  title={Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma},
  author={Xiezhao Li and Peng Xu and Chongshan Wang and Naijin Xu and Abai Xu and Yawen Xu and Takuya Sadahira and Motoo Araki and Koichiro Wada and Eiji Matsuura and Masami Sodegaura-shi Watanabe and Junxia Zheng and Pinghua Sun and Peng Huang and Yasutomo Nasu and Chunxiao Liu},
  booktitle={Oncotarget},
  year={2017}
}
Renal cell carcinoma (RCC) management has undergone a major transformation over the past decade; immune checkpoint inhibitors are currently undergoing clinical trials and show promising results. However, the effectiveness of immune checkpoint inhibitors in patients with metastatic RCC (mRCC) is still limited. Lycorine, an alkaloid extracted from plants of the Amaryllidaceae family, is touted as a potential anti-cancer drug because of its demonstrative growth inhibition capacity (induction of… CONTINUE READING
5
Twitter Mentions

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2015
VIEW 1 EXCERPT

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

  • The New England journal of medicine
  • 2015
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…